Investigational drug · Phase 2
ORIC-114
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ORIC-114"
First trial start
2022
Mar 10, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ORIC-114", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ORIC-114" as an intervention, largest first.
- Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationRecruiting
ORIC PharmaceuticalsIndustry
NCT05315700 · 350 participants (planned) · Start Mar 10, 2022 · Primary completion Jun 2027
Drug: ORIC-114; Chemotherapy drug · For: Solid Tumors
Sites: Duarte, California; Huntington Beach, California; Irvine, California · 42 sites in all
ORIC PharmaceuticalsIndustry
NCT06816992 · 76 participants (planned) · Start Feb 27, 2025 · Primary completion Dec 2026
Drug: ORIC-114 Dose 1 + amivantamab; ORIC-114 Dose 2 + amivantamab and 1 more · For: Solid Tumors; EGFR Exon 20 Insertion Mutations; NSCLC and 1 more
Sites: New York, New York; Fairfax, Virginia; Melbourne, Australia · 4 sites in all
ORIC PharmaceuticalsIndustry
NCT06012721 · 32 participants · Start Sep 11, 2023 · Primary completion Nov 23, 2023
Drug: ORIC-114 · For: Food Effect in Healthy Participants
Sites: Geelong, Australia; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
Junttila MR, Repellin CE, Salaniwal S, et al. · Cancer Res 2026
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.